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Abstract The discovery of at least 29 genes encoding putative 
guanylyl cyclases in Caenorhabditis elegans has raised the 
question as to whether there are numerous receptors yet to be 
discovered in the mammal. The nematode, however, not only 
seems ideal to study guanylyl cyclase receptor localization and 
function, given the large variety of isoforms, but also leads to 
possible identification of ligands for orphan guanylyl cyclases by 
the use of genetic and behavioral assays. A recent powerful 
approach to describe the function of different guanylyl cyclase 
isoforms in mammals has been the disruption of the correspond-
ing genes in the mouse. A salt resistant elevation of blood 
pressure, which corresponds to the phenotype of 50% of all 
human patients with essential hypertension, is observed in mice 
lacking the GC-A-receptor. Mice missing the GC-C receptor 
have been shown to be resistant to STa, an E. coli heat-stable 
enterotoxin, which is largely responsible for travellers diarrhea in 
adults and mortality due to diarrhea in infants. 
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1. Introduction 
Following the discovery of cyclic GMP in 1963 [1], guanylyl 
cyclase activity was found in both the particulate and soluble 
fractions of various tissue homogenates [2-4]. It was assumed 
that the Second Messenger Hypothesis for cAMP established 
by Sutherland and coworkers [5] would also apply for the 
regulation of cGMP. Therefore, it was speculated that hor-
mones which would elevate cyclic GMP in intact cells also 
would activate guanylyl cyclase in broken cell preparations; 
however, initial experiments met with failure. It eventually 
became evident that guanylyl cyclases were different from ad-
enylyl cyclases in that the ligand binding (receptor) and effec-
tor (cyclase) domain reside within the same molecule. Over 
the last 20 years both the membrane and soluble forms have 
been shown to be directly activated by various ligands in 
broken cell as well as in purified enzyme preparations. 
The membrane and soluble forms of guanylyl cyclase pos-
sess unique primary structures that appear consistent for each 
of the subfamily members across wide evolutionary distances; 
these structures are summarized in Fig. 1. 
In the mammal there are six membrane forms (GC-A-F) 
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and two cc (oci, CC2) and two P (pi, P2) subunits of the hetero-
dimeric soluble form identified [6]. For three of the six mem-
brane forms (GC-A-C) ligands have been identified, which fall 
into two families: the natriuretic peptides, and the heat-stable 
enterotoxins of E. coli, for which the endogenous homologs 
have been suggested as guanylin/uroguanylin [7,8]. The best 
characterized form of the soluble guanylyl cyclase, the oci/Pi-
heterodimer, is stimulated by binding of nitric oxide to a 
prosthetic heme group [9-11]. Recently another gaseous mol-
ecule, carbon monoxide has been proposed as a ligand for 
soluble guanylyl cyclase [12,13]. 
2. Functions of guanylyl cyclase receptors 
2.1. Orphan receptors 
There are different approaches to gain insight into the func-
tion of the various guanylyl cyclase receptors, including the 
discovery of ligands for the orphan receptors. In the mammal, 
two orphan receptors exist in the retina (GC-E, GC-F; [14-
16]), and one in the olfactory neuroepithelium (GC-D; [17]). 
GC-D is expressed in a subset of neurons that appear unique 
compared to the majority of sensory neurons found in the 
nose [18]. Determination of the function of GC-D may require 
the identification of its ligand, but since the ligand may be a 
pheromone/odorant, this likely represents a daunting task, 
given a ligand has not yet been identified for one of the 
mammalian 7-transmembrane, putative odorant receptors. In 
Caenorhabditis elegans, in contrast, the apparent 7-transmem-
brane receptor for diacetyl has been discovered [19]. We ini-
tiated studies on the nematode (C elegans) to determine 
whether guanylyl cyclase receptors were present, and if so, 
whether any existed within sensory neurons. A C. elegans 
cDNA library initially yielded a single clone encoding a pu-
tative membrane form of guanylyl cyclase [20]. The cDNA 
was then expressed in COS-7 cells to demonstrate that the 
clone actually encoded a protein with guanylyl cyclase activ-
ity. Subsequent searches of the C. elegans genome database 
revealed the presence of at least 29 gene products that ap-
peared to encode guanylyl cyclases. By the use of green fluo-
rescent protein (GFP) as a reporter gene product, it was 
shown that many of these orphan guanylyl cyclases are ex-
pressed in distinct sensory neurons (Fig. 2; [21]). In some 
cases, even neurons previously thought to be symmetrical, 
expressed orphan guanylyl cyclase receptors on only the right 
or the left side [21]. These results raise the question of whether 
guanylyl cyclase receptors play a major role in odorant/pher-
omone signaling and/or whether they function in other neuro-
nal processes. The fact that the nematode genome is about 1/ 
30 the size of the mammalian genome also raises the question 
of whether there are many more guanylyl cyclase receptors 
still to be discovered in the mammal. 
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Fig. 2. Expression of promoter::green fluorescent protein (GFP) in C. elegans. The promoters for membrane guanylyl cyclases GCY-6, GCY-7, 
GCY-8, or GCY-33 were used to drive the expression of GFP. The GCY-33 product is predicted to be a soluble form of guanylyl cyclase, 
most closely resembling the |3 subunit from mammals. The bright green images presumably represent sites of expression of each of the orphan 
guanylyl cyclases in different sensory neurons. 
2.2. Dominant negative mutants 
Both the cytoplasmic and membrane forms of guanylyl cy-
clase appear to exist as dimers or higher ordered structures, 
and thus various mutations have led to the formation of dom-
inant negative subunits. In some cases these have been muta-
tions which inactivate cyclase catalytic activity [22,23] while in 
other cases they have prevented ligand stimulation [24]. 
Although these mutant subunits have yet to be successfully 
used as reagents to define the importance of any particular 
cyclase signaling pathway, their overexpression in transgenic 
animals or in virus-infected tissues or cells, in principal, could 
help define the functions of various cyclase receptor signaling 
pathways. Furthermore, that a single point mutation in one 
subunit can inactivate the cyclase suggests that a single sub-
strate (GTP) molecule is bound through shared subunit bind-
ing sites. Thus, it has been proposed that a dimer is the min-
imal catalytic unit of either adenylyl or guanylyl cyclases 
[10,11]. 
2.3. Constitutively active mutants 
There are two types of general mutations which appear to 
lead to constitutively active membrane forms of guanylyl cy-
clase. The first is deletion of the protein kinase-like domain 
[25], and the second is mutation of Glu974Ala, both in GC-A 
[26]. Since GC-A lacking the protein kinase-like domain is 
active and no longer regulated by ANP/ATP, it has been 
suggested that the protein kinase domain normally serves to 
repress the activity of the cyclase catalytic domain and that 
ANP/ATP relieve this inhibition [25]. The point mutation 
(E974A) results in about a 14-fold increase in GC-A activity, 
which is observed even in the presence of Mn2+/Triton X-100 
[26]. The elevated cyclase activity is not explained by relief of 
protein kinase domain inhibition since a mutant protein lack-
ing the protein kinase-like domain also expresses high cyclase 
activity. Unlike the protein kinase-like domain deletion mu-
tant, the point mutant (E974A) also converts the kinetic pat-
Fig. 1. The predicted primary structures of soluble and membrane guanylyl cyclases. All guanylyl cyclase isoforms contain a carboxyl terminal 
consensus catalytic domain (CAT), which is homologous to the catalytic domain of adenylyl cyclase. Another common feature of all guanylyl 
cyclases is an amphipathic, predicted a-helical dimerization domain (hinge region; H) The soluble forms appear to exist only as heterodimers, 
and demonstrate no catalytic activity unless the dimer is formed [11]. While the Pi subunit dimerizes with the di and 0:2 subunits, a partner 
for the p2 subunit has not yet been identified. The amino terminus likely binds heme [24], the site of interaction with the ligands NO and CO. 
The membrane forms appear to contain a single transmembrane segment that separates an extracellular ligand-binding domain (ECD) from in-
tracellular protein kinase-like (KHD), hinge (H) and cyclase catalytic domains (CAT). The membrane forms appear to exist as homodimers or 
higher ordered homomers [32]. 
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Fig. 3. A: Salt-resistant hypertension in GC-A null mice. Systolic 
blood pressure is significantly elevated in the heterozygous and ho-
mozygous null mice but is resistant to changes in dietary salt. B: 
Resistance to STa-induced diarrhea in GC-C null mice. The suck-
ling mouse assay [31] was used to assess the response to sham, STa 
or cholera toxin (CT) treatment. Whereas wild-type mice display 
marked accumulation of fluid within the intestine in response to 
STa, the GC-C null mice fail to respond to the enterotoxigenic 
agent. Cholera toxin, however, which acts through the cAMP sig-
nalling pathway, continues to cause diarrhea in GC-C null mice. It 
is concluded that GC-C is the receptor that mediates the diarrhetic 
response to STa. Diarrhea is defined as gut/carcass weight over 
0.083 (8.3%). 
tern from concave upward to linear as a function of MnGTP 
concentration [26]. 
2.4. Gene disruption 
Although there are many caveats to interpretations of func-
tion based on disruption of a gene, it offers a means to inter-
rupt a signaling pathway in the intact animal and to poten-
tially identify a corresponding phenotype in the human in 
addition to unraveling the functions of the signaling pathway. 
2.4.1. GC-A gene disruption. GC-A deficient mice display 
a salt-resistant form of hypertension (Fig. 3A; [27]). The gene 
for ANP, an apparent ligand of GC-A, also has been dis-
rupted, and although the initial phenotype was reported as 
a salt-sensitive form of hypertension [28], later studies sug-
gested that the mice displayed a phenotype more consistent 
with that of the GC-A null mice [29]. The salt-resistant hyper-
tension raised the question of whether another receptor for 
ANP existed within the kidney or whether the heart could 
release other natriuretic/diuretic factors in response to in-
creased vascular volume. Infusion of ANP failed to cause 
natriuresis or diuresis in the GC-A null mice suggesting that 
GC-A is the exclusive ANP receptor in the kidney. Expansion 
of vascular volume by intravenous infusion of an isoncotic 
solution resulted in release of granules from the heart; how-
ever, there again was no diuresis or natriuresis, thus suggest-
ing that GC-A is the primary receptor in the kidney for any 
substance that might be released from the heart to mediate 
natriuresis/diuresis under conditions of acute volume expan-
sion [30], at least when volume is expanded through intrave-
nous infusion. 
2.4.2. GC-C gene disruption. GC-C is expressed princi-
pally in the intestine of the mouse. Heat stable enterotoxins 
(STa), which cause an acute secretory diarrhea, have been 
suggested to mediate their actions through the guanylyl cy-
clase-C (GC-C) receptor. The GC-C gene was disrupted by 
homologous recombination and homozygous null mice con-
tained no detectable GC-C mRNA or protein [31]. Intestinal 
mucosa guanylyl cyclase activity was about 16-fold higher in 
wild-type mice than in the GC-C null mice suggesting that 
GC-C is the major guanylyl cyclase activity present in the 
intestine. It has been a point of controversy for some years 
whether there are multiple receptors for STa that mediate 
diarrhea. When 125Sta binding or STa-stimulable guanylyl cy-
clase activity was measured, however, it was about one-half 
wild-type mice in heterozygous animals and absent in the GC-
C null animals. Thus, GC-C completely accounts for the STa-
induced elevations of cGMP. While gavage with STa results in 
marked fluid accumulation within the intestine of wild-type 
and heterozygous suckling mice, GC-C null animals are resist-
ant to such treatment (Fig. 3B). In addition, infection with 
enterotoxigenic bacteria that produce STa leads to diarrhea 
and death in wild-type and heterozygous mice, while the null 
mice are protected. Cholera toxin, in contrast, continues to 
cause diarrhea in GC-C null mice, demonstrating that the 
cAMP signaling pathway remained intact. Markedly different 
diets (high carbohydrate, fat, or protein) or the inclusion of 
high salt (K+, Na+) in the drinking water or diet also did not 
severely affect the null animals. Given that GC-C is a major 
intestinal receptor in all mammals, the pressure to retain a 
functional GC-C in the face of diarrhea-inflicted mortality 
remains unexplained. GC-C, therefore, likely provides a nec-
essary protective effect against stressors not yet tested, possi-
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bly pathogens other than non-invasive enterotoxigenic bacte-
ria. 
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